Figure 1

Growth inhibition of human colon tumor xenografts by irinotecan. Subcutaneous xenograft-bearing mice were treated with irinotecan intraperitoneally at 40 mg/kg q5dx5 on the days indicated by arrows. Tumor growth was evaluated by plotting the mean relative tumor volume ± SEM (n = 8–l10) over time. Two representative examples of xenografts that exhibited different levels of in vitro sensitivity to SN-38 (the active metabolite of irinotecan) are shown (see Table 2). The control (C), treated (T) and regrowth (R) samples used for transcriptome analysis are indicated in the corresponding curves. Four to five mice, each bearing two individual tumor xenografts, were included in each group. Results were confirmed in two independent experiments.